Uppsala, Sweden – October 8, 2018 – Prior to the Annual General Meeting 2019, Orexo appoints a Nomination Committee which represents approximately 45 percent of the number of shares and votes in the company based on the last known shareholder information.
The Nomination Committee, whose tasks include providing proposals to the General Meeting regarding Chairman of the Meeting, Board members, Chairman of the Board, fees for the board members, any remuneration for committee work, proposal for and fees to the company’s auditor as well as principles for composition of the Nomination Committee, comprises:
- Michael Shalmi, Novo Holdings A/S, also Chairman of the Nomination Committee
- Björn Odlander, HealthCap
- Claus Berner Møller, Arbejdsmarkedets Tillaegspension (ATP)
- Martin Nicklasson, Chairman of the Board of Orexo
The Nomination Committee’s proposals will be presented in the Notice to the Annual General Meeting 2019 and on Orexo’s website, www.orexo.com.
Shareholders who want to submit proposals to the Nomination Committee, can do this by sending an e-mail to moc.o1550671583xero@1550671583ri1550671583 (subject “Nomination Committee”) or by letter posted to “Orexo’s Nomination Committee”, Orexo AB, P.O. Box 303, SE-751 05 Uppsala, Sweden, by February 8, 2019 at the latest.
The Annual General Meeting 2019 in Orexo will be held on Thursday, April 11, 2019 at 4:00 pm CET in Uppsala. Shareholders who want to have a matter addressed at the Annual General Meeting 2019 must submit such a proposal to the same address as above (subject “Annual General Meeting 2019” for the e-mail and the letter, respectively) by March 1, 2019 at the latest.
Future information reporting dates from Orexo:
|Interim Report Q3 2018||October 25, 2018 at 8.00 am CET|
|Year-End Report 2018||January 30, 2019 at 8.00 am CET|
|Publication of the Annual Report||March week 12, 2019|
|Annual General Meeting 2019||April 11, 2019 at 4:00 pm CET|
|Interim Report Q1 2019||May 2, 2019 at 8.00 am CET|
|Interim Report Q2 2019||July 11, 2019 at 8.00 am CET|
For further information, please contact:
Orexo AB (publ.)
|Henrik Juuel, EVP and CFO||Lena Wange, IR & Communications Manager|
|Tel: +46 (0)18 780 88 00||Tel: +46 (0)18 780 88 00|
|E-mail: moc.o1550671583xero@1550671583ri1550671583||E-mail: moc.o1550671583xero@1550671583ri1550671583|
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.
The information was submitted for publication at 5.45 pm CET, on October 8, 2018.